Glaxo to pay $750 million for sale of bad products
GlaxoSmithKline, the British drug giant, has agreed to pay $750 million to settle criminal and civil complaints that the company for years knowingly sold contaminated baby ointment and an ineffective antidepressant — the latest in a growing number of whistle-blower lawsuits that drug makers have settled with multimillion-dollar fines.
Altogether, GlaxoSmithKline sold 20 drugs with questionable safety that were made at a huge plant in Puerto Rico that for years was rife with contamination.
- As Retail Clinics Surge, Quality Metrics MIA
- Providers' Push to Consolidate Roils Payers
- Former NQF Co-Chair Linked to Conflicts of Interest in Journal Probe
- 6 Not-So-Good Reasons for Avoiding Population Health
- Medicare Cost, Quality Data Tools Weak, Says GAO
- No Employee Satisfaction, No Patient-Centered Culture
- RN Named Chief Patient Experience Officer
- Population Health Pays Off for NY Collaborative
- In PCMH, the 'P' is Not for 'Physician'
- How Simple Data Analytics is Driving Physician Incentives